Existing HIV antiretroviral therapies are mostly small-molecule drugs that require daily medication. Broadly neutralizing antibodies (bNAbs) hold promise as potential longer-term options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,